A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients
Authors:
- 1 February 2021
- journal article
- research article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 110 (4) , 1082-1089
Abstract
No abstract availableKeywords
Funding Information
- Boston Scientific Corporation
- Pfizer
- International Association for Bear Research and Management
- Medtronic
- National Institutes of Health
- National Cancer Institute
- Varian Medical Systems
This publication has 29 references indexed in Scilit:
- Ten-Year Update of a Randomized, Prospective Trial of Conventional Fractionated Versus Moderate Hypofractionated Radiation Therapy for Localized Prostate CancerJournal of Clinical Oncology, 2020
- Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based GuidelineJournal of Clinical Oncology, 2018
- Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate CancerJournal of Clinical Oncology, 2018
- Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trialAdvances in Radiation Oncology, 2017
- Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysisPractical Radiation Oncology, 2017
- Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate CancerJournal of Clinical Oncology, 2017
- Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trialThe Lancet Oncology, 2016
- Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trialThe Lancet Oncology, 2016
- Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate CancerJournal of Clinical Oncology, 2016
- Dose-Fractionation Sensitivity of Prostate Cancer Deduced From Radiotherapy Outcomes of 5,969 Patients in Seven International Institutional Datasets: α/β = 1.4 (0.9–2.2) GyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012